Briumvi (ublituximab) has been launched in Ireland for the treatment of adult patients with relapsing multiple sclerosis (RMS) with active disease, defined by clinical or imaging features.  

 

Ublituxima is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of RMS. Ublituxima is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion. 

 

In clinical studies, patients who received ublituxima had a median B-cell depletion of 97% 24 hours after the first dose.

 

Briumvi is administered as a one-hour infusion twice per year following an initial dose (administered over four hours), thereby limiting the time spent in the infusion suite for the patient and reducing the burden on the healthcare provider. 

 

Briumvi was launched by Neuraxpharm Ireland, part of Neuraxpharm Group, a European speciality pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, both psychiatric and neurological.

 

For further information email: Fidelma Loftus at floftus@neuraxpharm.com